CNMD PE Ratio & Valuation,Is CNMD Overvalued

CNMD Relative Valuation

CNMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CNMD is overvalued; if below, it's undervalued.

Historical Valuation

Conmed Corp (CNMD) is now in the Undervalued zone, suggesting that its current forward PE ratio of 9.26 is considered Undervalued compared with the five-year average of 26.53. The fair price of Conmed Corp (CNMD) is between 174.93 to 253.17 according to relative valuation methord. Compared to the current price of 40.83 USD , Conmed Corp is Undervalued By 76.66%.

Relative Value

Fair Zone

174.93-253.17

Current Price：40.83

76.66%

Undervalued

9.14

7.92

EV/EBITDA

Conmed Corp. (CNMD) has a current EV/EBITDA of 7.92. The 5-year average EV/EBITDA is 15.63. The thresholds are as follows: Strongly Undervalued below 6.14, Undervalued between 6.14 and 10.89, Fairly Valued between 20.38 and 10.89, Overvalued between 20.38 and 25.13, and Strongly Overvalued above 25.13. The current Forward EV/EBITDA of 7.92 falls within the Undervalued range.

9.88

EV/EBIT

Conmed Corp. (CNMD) has a current EV/EBIT of 9.88. The 5-year average EV/EBIT is 20.88. The thresholds are as follows: Strongly Undervalued below 7.65, Undervalued between 7.65 and 14.26, Fairly Valued between 27.49 and 14.26, Overvalued between 27.49 and 34.10, and Strongly Overvalued above 34.10. The current Forward EV/EBIT of 9.88 falls within the Undervalued range.

0.91

Conmed Corp. (CNMD) has a current PS of 0.91. The 5-year average PS is 2.44. The thresholds are as follows: Strongly Undervalued below 0.56, Undervalued between 0.56 and 1.50, Fairly Valued between 3.37 and 1.50, Overvalued between 3.37 and 4.31, and Strongly Overvalued above 4.31. The current Forward PS of 0.91 falls within the Undervalued range.

7.61

P/OCF

Conmed Corp. (CNMD) has a current P/OCF of 7.61. The 5-year average P/OCF is 24.12. The thresholds are as follows: Strongly Undervalued below 3.12, Undervalued between 3.12 and 13.62, Fairly Valued between 34.61 and 13.62, Overvalued between 34.61 and 45.11, and Strongly Overvalued above 45.11. The current Forward P/OCF of 7.61 falls within the Undervalued range.

7.07

P/FCF

Conmed Corp. (CNMD) has a current P/FCF of 7.07. The 5-year average P/FCF is 25.67. The thresholds are as follows: Strongly Undervalued below -0.74, Undervalued between -0.74 and 12.46, Fairly Valued between 38.87 and 12.46, Overvalued between 38.87 and 52.07, and Strongly Overvalued above 52.07. The current Forward P/FCF of 7.07 falls within the Undervalued range.

Conmed Corp (CNMD) has a current Price-to-Book (P/B) ratio of 1.25. Compared to its 3-year average P/B ratio of 2.94 , the current P/B ratio is approximately -57.37% higher. Relative to its 5-year average P/B ratio of 3.70, the current P/B ratio is about -66.14% higher. Conmed Corp (CNMD) has a Forward Free Cash Flow (FCF) yield of approximately 11.78%. Compared to its 3-year average FCF yield of 5.22%, the current FCF yield is approximately 125.80% lower. Relative to its 5-year average FCF yield of 3.96% , the current FCF yield is about 197.56% lower.

1.24

P/B

Median3y

2.94

Median5y

3.70

11.78

FCF Yield

Median3y

5.22

Median5y

3.96

Competitors Valuation Multiple

The average P/S ratio for CNMD's competitors is , providing a benchmark for relative valuation. Conmed Corp Corp (CNMD) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 6.70%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CNMD decreased by 41.09% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 13.40 to 19.66.

The secondary factor is the Revenue Growth, contributed 6.70%to the performance.

Overall, the performance of CNMD in the past 1 year is driven by P/E Change. Which is more unsustainable.

6.70%

316.70M → 337.93M

Revenue Growth

-94.51%

15.47 → 0.85

Margin Expansion

46.72%

13.40 → 19.66

P/E Change

-41.09%

68.44 → 40.32

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Conmed Corp (CNMD) currently overvalued or undervalued?

What is Conmed Corp (CNMD) fair value?

CNMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Conmed Corp (CNMD) is between 174.93 to 253.17 according to relative valuation methord.

How does CNMD's valuation metrics compare to the industry average?

What is the current P/B ratio for Conmed Corp (CNMD) as of Dec 16 2025?

As of Dec 16 2025, Conmed Corp (CNMD) has a P/B ratio of 1.25. This indicates that the market values CNMD at 1.25 times its book value.

What is the current FCF Yield for Conmed Corp (CNMD) as of Dec 16 2025?

As of Dec 16 2025, Conmed Corp (CNMD) has a FCF Yield of 11.78%. This means that for every dollar of Conmed Corp’s market capitalization, the company generates 11.78 cents in free cash flow.

What is the current Forward P/E ratio for Conmed Corp (CNMD) as of Dec 16 2025?

As of Dec 16 2025, Conmed Corp (CNMD) has a Forward P/E ratio of 9.26. This means the market is willing to pay $9.26 for every dollar of Conmed Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Conmed Corp (CNMD) as of Dec 16 2025?

As of Dec 16 2025, Conmed Corp (CNMD) has a Forward P/S ratio of 0.91. This means the market is valuing CNMD at $0.91 for every dollar of expected revenue over the next 12 months.

CNMD Valuation